Baird lowered the firm’s price target on Contineum (CTNM) to $16 from $32 and keeps an Outperform rating on the shares. The firm said its Phase 2 results in relapsing-remitting MS is on track ...

“2025 is shaping up to be a pivotal year, as we have several important clinical data readouts and trial initiations on the horizon,” said Carmine Stengone, CEO, Contineum (CTNM) Therapeutics.

CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications ...

These 12 undervalued financial-services stocks look attractive today. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a ...

SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the ...

Event has submitted the required documentation for a permit, this has been reviewed and a permit has been issued by British Triathlon. This is an indoor event. Both run and cycle elements will be ...